The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma.

[1]  M. Tamaki,et al.  Molecular forms of human brain natriuretic peptide in plasma. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[2]  H. Teraoka,et al.  Erratum to “Degradation of human brain natriuretic peptide (BNP) by contact activation of blood coagulation system” [Clin. Chim. Acta 305 (2001) 181–186] , 2001 .

[3]  U. Janssens,et al.  Evaluation of a new, rapid bedside test for quantitative determination of B-type natriuretic peptide. , 2001, Clinical chemistry.

[4]  N. Valli,et al.  Stability of Brain Natriuretic Peptide (BNP) in Human Whole Blood and Plasma , 2000, Clinical chemistry and laboratory medicine.

[5]  M. Yacoub,et al.  Cardiac peptide stability, aprotinin and room temperature: importance for assessing cardiac function in clinical practice. , 1999, Clinical science.

[6]  H. Teraoka,et al.  Stability of brain natriuretic peptide (BNP) in human blood samples. , 1999, Clinica chimica acta; international journal of clinical chemistry.

[7]  D. Murdoch,et al.  Disparity between studies of the stability of BNP in blood: comparison of endogenous and exogenous peptide , 1999, Heart.

[8]  P. Taskinen.  Mapping the cellular mechanisms regulating atrial natriuretic peptide secretion , 1999 .

[9]  R. Levin,et al.  Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease. , 1998, American heart journal.

[10]  H. Dargie,et al.  Biochemical detection of systolic dysfunction , 1998, The Lancet.

[11]  D. Gardner,et al.  N ATRIURETIC P EPTIDES , 1998 .

[12]  J. McMurray,et al.  Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: implications for clinical practice , 1997, Heart.

[13]  D. Fukai,et al.  Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. , 1997, Circulation.

[14]  S. Anker,et al.  Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. , 1997, Circulation.

[15]  K. Kugiyama,et al.  Localization and Mechanism of Secretion of B‐Type Natriuretic Peptide in Comparison With Those of A‐Type Natriuretic Peptide in Normal Subjects and Patients With Heart Failure , 1994, Circulation.

[16]  K. Inouye,et al.  Stabilization of human brain natriuretic peptide in blood samples. , 1994, Clinical chemistry.

[17]  A. Kenny,et al.  Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. , 1993, The Biochemical journal.

[18]  K. Nakao,et al.  Human brain natriuretic peptide, a novel cardiac hormone , 1990, The Lancet.

[19]  J. Almenoff,et al.  Membrane-bound kidney neutral metalloendopeptidase: interaction with synthetic substrates, natural peptides, and inhibitors. , 1983, Biochemistry.

[20]  A. Barrett,et al.  Human plasma kallikrein. A rapid purification method with high yield. , 1981, The Biochemical journal.